Drug Profile
Research programme: enzyme replacement therapies - Valerion Therapeutics
Alternative Names: 3E10Fab-GAA - Valerion Therapeutics; 3E10fv-MTM1 fusion protein - Valerion Therapeutics; 4s3-001; 4s3-002; 4s3-004; 4s3-005; VAL 0524; VAL-0411; VAL-0417; VAL-0620; VAL-1205Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator 4s3 Bioscience
- Developer Valerion Therapeutics
- Class Antineoplastics; Enzymes; Proteins
- Mechanism of Action Enzyme replacements; Protein replacements; Tumour suppressor protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Congenital structural myopathies; Lafora disease; Myotonic dystrophy; Neurofibromatosis 1
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Lafora disease in USA (Intraventricular, Injection)
- 28 Aug 2020 No recent reports of development identified for research development in Neurofibromatosis-1 in USA
- 28 Aug 2018 No recent reports of development identified for preclinical development in Congenital structural myopathies in USA (Parenteral)